Rene Russo - 22 Feb 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
CEO AND PRESIDENT, Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 16:30:15 UTC
Previous filing
04 Jan 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 22 Feb 2022 Common Stock 150,000 $12.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026.